More than 4 out of 10 dementia patients with Alzheimer's disease stop taking therapeutic drugs within a year of starting ...

MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA ...

Jupiter Hospital recently managed a rare and challenging case of NMDA receptor positive autoimmune encephalitis in a ...

A systematic review and meta-analysis of over 140 studies sheds light on which drug classes, including NMDA-receptor antagonists and VGSC blockers, can reduce secondary hyperalgesia.

Autism spectrum disorder (ASD) is widely known for its core features, which include difficulties in social communication and ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 12:40 PM EDT ...

An update from MIRA Pharmaceuticals, Inc. ( ($MIRA) ) is now available. MIRA Pharmaceuticals announced positive results from a proof-of-concept ...

Nutritionist Lovneet Batra shares some common dietary inputs that cause brain fog and how you can reverse it with targeted lifestyle changes.

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Good morning, everyone, and welcome to Morgan Stanley's Global ...

Alternative splicing of hundreds of genes in neurons generates isoforms essential for synaptic plasticity during a critical ...

SaveHealth reports on depression medications, emphasizing individual responses to treatments and the importance of combining meds with therapy for optimal outcomes.

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is ...